Daniel P. Petrylak, MD, presented “Novel Targeted Treatment and Its Integration with Precision Diagnostics” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Petrylak, Daniel P. “Novel Targeted Treatment and Its Integration with Precision Diagnostics.” September 22, 2023. Accessed Aug 2024. https://grandroundsinurology.com/novel-targeted-treatment-and-its-integration-with-precision-diagnostics/
Novel Targeted Treatment and Its Integration with Precision Diagnostics – Summary
Daniel P. Petrylak, MD, outlines challenges in treating prostate cancer, particularly the disease’s heterogeneity and conventional therapies’ limitations. He asserts that novel targeted treatments, including next-generation androgen receptor inhibitors, PARP inhibitors, and radioligand therapies, show promise in overcoming these challenges.
Dr. Petrylak explains how techniques such as next-generation sequencing, liquid biopsies, and multi-parametric MRI can identify actionable mutations and biomarkers that guide the selection of targeted therapies. This precision approach ensures that treatments are tailored to the specific characteristics of each patient’s cancer, maximizing efficacy and minimizing unnecessary side effects. He highlights cases where patients with specific genetic alterations, such as BRCA mutations, have responded exceptionally well to targeted therapies like PARP inhibitors. These examples underscore the potential for precision medicine to transform prostate cancer treatment by offering more personalized and effective therapeutic options.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
